newsfilter
← Latest News
Business Wire·

Coya Therapeutics Announces Completion of Full Enrollment in Phase 2/3 ALSTARS Trial of COYA 302 for the Treatment of ALS

120th participant has been enrolled in ALSTARS trial achieving target enrollment Additional eligible participants already in active screening will be allowed to enroll Topline data from 24-week double-blind